| | 
Part, Chapter, Paragraph
1 II, 5. 2. 5| resolutions and charters (EUR/RC56/R2; WHA53.17; EUR/RC52/
2 II, 5. 2. 5| EUR/RC56/R2; WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/
3 II, 5. 2. 5| WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/
4 II, 5. 2. 5| EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have
5 II, 5. 2. 5| EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have been adopted
6 II, 5. 2. 7| from the EUROCISS Project. Eur J Public Health 13: 55-60~
7 II, 5. 2. 7| practice: executive summary. Eur Heart J 28: 2375-414~Greenland
8 II, 5. 2. 7| Union between 1970 and 2000. Eur Heart J 27: 107-113.~Kuulasmaa
9 II, 5. 2. 7| from the Progetto CUORE. Eur J Cardiovasc Prev Rehabil
10 II, 5. 2. 7| morbidity statistics in Europe. Eur Heart J 18: 1231–48.~Sarti
11 II, 5. 3. 9| cancer health indicators. Eur J Public Health 13(3 Suppl):
12 II, 5. 5. 1| Sweden from 1997 to 2005. Eur Psychiatry 22(3):146-52.~ ~S G (
13 II, 5. 5. 3| of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~
14 II, 5. 5. 3| psychotic disorders in Europe. Eur J Neurol 12 Suppl 1:74-77.~
15 II, 5. 5. 3| psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci
16 II, 5. 5. 3| between research and care. Eur Arch Psychiatry Clin Neurosci
17 II, 5. 5. 3| Europe – a systematic review. Eur J Neurol 12:245-253.~Fraser
18 II, 5. 5. 3| Csongrád County, Hungary. Eur Neurol 46:206-209.~Benedikz
19 II, 5. 5. 3| incidence over a 25-year period. Eur J Neurol 8:463-469.~Confavreux
20 II, 5. 5. 3| trends, and prospects. Eur J Neurol 11:511–520~EUROPA.
21 II, 5. 5. 3| Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78-105~
22 II, 5. 5. 3| province of Evros, Greece. Eur Neurol 49:8-12.~Poser CM,
23 II, 5. 5. 3| multiple sclerosis in Europe. Eur J Neurol 13: 700–722.~Pugliatti
24 II, 5. 5. 3| of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~
25 II, 5. 5. 3| uncomplicated) Parkinson’s disease. Eur J Neurol 13(11):1170-1185.~
26 II, 5. 5. 3| Parkinson’s disease in Europe. Eur J Neurol 12 Suppl 1:68-73.~
27 II, 5. 5. 3| Parkinson’s disease in Europe. Eur Neuropsychopharmacol 15(
28 II, 5. 6. 6| symptoms in a local community. Eur J Gen Pract 1:25-28~Naz
29 II, 5. 7. 7| the general population. Eur Heart J 2006 May;27(10):
30 II, 5. 8. 7| exposed to inorganic dust~Eur Respir J 23: 402-406.~ ~
31 II, 5. 8. 7| Chronic Respiratory Diseases.~Eur Respir J 2007; 29: 233-239.~ ~
32 II, 5. 8. 7| ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.~ ~
33 II, 5. 8. 7| phlegm in young adults. Eur Respir J 2003; 22: 413-417.~ ~
34 II, 5. 8. 7| obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207.~ ~
35 II, 5. 8. 7| review and meta-analysis. Eur Respir J 2006; 28: 523-532.~ ~
36 II, 5. 8. 7| multiple cause coding analysis. Eur Respir J 2003; 22: 809-814.~ ~
37 II, 5. 8. 7| research in Europe: FP7. Eur Respir J 2007; 29: 223-225.~ ~
38 II, 5. 8. 7| what's the difference? Eur J Public Health 2006; 16:
39 II, 5. 8. 7| sample: the NICECOPD study. Eur J Epidemiol 2005; 20: 443-
40 II, 5. 8. 7| disease”. Siafakas NM eds. Eur Respir Mon, Monograph 38,
41 II, 5. 8. 7| natural history of COPD. Eur Respir J 2007; 30: 993–1013~ ~
42 II, 5. 8. 7| with smoking cigarettes. Eur J Epidemiol 2004; 19: 147-
43 II, 5. 8. 7| Increasing COPD awareness. Eur Respir J 2006; 27: 833-852.~ ~
44 II, 5. 9. 7| 1996): The costs of asthma. Eur Respir J. 2006 Apr;9(4):
45 II, 5. 9. 7| Respiratory Health Survey. Eur Respir J, 1994, 7, 954-960~ ~
46 II, 5. 9. 7| Survey-II Steering Committee. Eur Respir J 2002; 20:1071-1079~ ~
47 II, 5. 9. 7| predictors: the RHINE study. Eur Respir J 2004; 24: 942-946~ ~To E,
48 II, 5. 10. 7| gluten in coeliac disease. Eur J Gastroenterol Hepatol
49 II, 5. 10. 7| symptoms in young adults. Eur Respir J 1998; 11(1):151-
50 II, 5. 10. 7| Survey (ECRHS) 1991-1994. Eur J Clin Nutr 2001; 55(4):
51 II, 5. 10. 7| allergy in the community. Eur J Clin Nutr; 56(1):31-36.~ ~
52 II, 5. 11. 3| skin diseases in Europe Eur J Dermatol 2006;16:212-218~ ~ ~
53 II, 5. 11. 7| from a European survey. J Eur Acad Dermatol Venereol 2005;
54 II, 5. 11. 7| review. Onychomycosis. J Eur Acad Dermatol Venereol.
55 II, 5. 11. 7| Vaud: an update, 1976–1998. Eur J Cancer Prev 2001;10:371–
56 II, 5. 11. 7| skin diseases in Europe Eur J Dermatol 2006:16:212-218.~ ~ ~ ~
57 II, 7. 5 | implementing resolution EUR/RC55/R9 during the past
58 II, 7. 7 | the WHO European Region. EUR/RC55/R9 of September 15,
59 II, 8. 2. 1| A European perspective. Eur J Public Health 13: 47-50;
60 II, 9. 1. 1| health outcomes in Europe. Eur J Obstet Gynecol Reprod
61 II, 9. 1. 1| hospitals: descriptive study. Eur J Obstet Gynecol Reprod
62 II, 9. 1. 1| Medical Experts Committee. Eur J Obstet Gynecol Reprod
63 II, 9. 1. 1| childbearing population in Europe. Eur J Obstet Gynecol Reprod
64 II, 9. 1. 1| study in The Netherlands. Eur J Obstet Gynecol Reprod
65 II, 9. 1. 1| a retrospective study. Eur J Obstet Gynecol Reprod
66 II, 9. 1. 1| from the PERISTAT project. Eur J Obstet Gynecol Reprod
67 II, 9. 1. 2| chlidbearing population in Europe. Eur J Obstet Gynecol Repr Biol,
68 II, 9. 2. 7| mortality in Europe, 1955—1995. Eur J Cancer. 37:785-809.~ ~
69 II, 9. 3. 1| Randomized Controlled Trial Eur Urol 51: 659-664~ ~Austbury
70 II, 9. 3. 2| health outcomes in Europe. Eur J Obstet Gynecol Reprod
71 II, 9. 3. 2| hospitals: descriptive study. Eur J Obstet Gynecol Reprod
72 II, 9. 3. 2| Medical Experts Committee. Eur J Obstet Gynecol Reprod
73 II, 9. 3. 2| childbearing population in Europe. Eur J Obstet Gynecol Reprod
74 II, 9. 3. 2| study in The Netherlands. Eur J Obstet Gynecol Reprod
75 II, 9. 3. 2| a retrospective study. Eur J Obstet Gynecol Reprod
76 II, 9. 3. 2| The Netherlands 1983-1992. Eur J Obstet Gynecol Reprod
77 II, 9. 3. 2| The REPROSTAT project. Eur J Obstet Gynecol Reprod
78 II, 9. 3. 2| from the PERISTAT project. Eur J Obstet Gynecol Reprod
79 II, 9. 3. 3| countries: a systematic review. Eur J Public Health. 0: ckm014v1-7~
80 II, 9. 3. 3| health education campaigns. Eur J Public Health 16(5):498-
81 III, 10. 2. 1| Respiratory Health Survey. Eur Respir J 2006; 27:517-524~ ~
82 III, 10. 2. 1| cohort study 1984-1992. Eur Heart J, 1998; 19: 1997-
83 III, 10. 2. 1| PEP) (ECE/AC.21/2002/9-EUR/02/5040828/9)-Geneva [htt ~ ~
84 III, 10. 2. 1| INN-CA Study 1994-1996. Eur. J. Clin. Nutr. 55 (7),
85 III, 10. 2. 1| Geneva, (ECE/AC.21/2002/9-EUR/02/5040828/9): (http://www.
86 III, 10. 2. 1| consumption survey method. Eur J Clin Nutr 56 Suppl 2:
87 III, 10. 3. 1| an overall cost of around EUR 4 billion (Boegli, 2006).~ ~
88 III, 10. 3. 1| mortality in Europe 1995. Eur. J. Cancer 38, 99-166.~Darby
89 III, 10. 4. 3| and International Lakes. EUR/ICP/EHCO 020205/8Fin, 18
90 IV, 12. 2 | resolutions and charters (EUR/RC56/R2; WHA53.17; EUR/RC52/
91 IV, 12. 2 | EUR/RC56/R2; WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/
92 IV, 12. 2 | WHA53.17; EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/
93 IV, 12. 2 | EUR/RC52/R12; EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have
94 IV, 12. 2 | EUR/RC55/R1; EUR/RC54/R3; EUR/RC55/R6) have been adopted
95 IV, 13. 7. 3| themes. The “Health” theme (EUR 6.0 billion) currently covers
96 IV, 13. 7. 3| the largest in FP7with EUR 9.1 billion - supports the
97 IV, 13. 7. 3| and biotechnology theme (EUR 1.9 billion), the food,
98 IV, 13. 7. 3| While the ERC is funded with EUR 7.5 billion over 7 years,
99 IV, 13. 9 | of the brain in Europe. Eur J Neurol 12 Suppl 1:1-27.~
|
|
| |
